gene, the product of the Ph chromosome, is found in the leukemic clone of at least 95% of CMLpatients diagnosed by conventional clinical features. The fusion protein encoded by BCRABLvaries in size, depending on the breakpoint in the BCR gene. Three breakpoint cluster regions have been characterized to date: major (M-bcr), minor (m-bcr) and micro (|i-bcr) (1) .
The smallest of the fusion proteins, pl90BCR-ABL(m-bcr breakpoint), is principally associated with Ph-positive ALL. Rare cases of CMLare due to a pl90-type of BCR-ABL gene and the disease tends to have a prominent monocytic component, resembling chronic myelomonocytic leukemia (CMML). Melo et al first reported the missing link of pl90BCR-ABL CMLwith CMML and pointed out that acute myeloid leukemia with m-bcr breakpoint also had a myelomonocytic phenotype (FAB M4) (2) . They speculated that it might indicate that the presence of pl90BCR-ABLin a committed early myeloid cell resulted in a myeloproliferative defect including monocytic lineage, whereas p210 BCR-ABL,the product of M-bcr breakpoint, in the same type of progenitor restricted the excessive proliferation to the granulocytic pathway. Thereafter sporadic cases of CMLwith p 1 90BCR-ABLhave been reported. Although the dual expression of major and minor BCR-ABLfusion transcript could be detectable in the vast majority of CMLpatients, CMLexpressing exclusively a minor BCR-ABL transcript had been rare and the incidence of this condition was observed in 5 of the 1,384 (0.36%) CML cases in one study (3) . Ohsaka et al reported a rare case of CMLwith pl90BCR-ABL and reviewed the literature of similar cases (4) .
See alsop 1183.
They grouped these 18 cases into two categories according to having prominent monocytosis or not. Ten patients with monocytosis had similar hematological and clinical features except monocytosis to those of the other 8 patients without it. Hur et al published a similar review including 23 patients with pl90BCR-ABL CML(5). They suggested that the absence of basophilia, and no or mild splenomegaly were the additional clinical features. Both authors pointed out the tendency to progression to lymphoid crisis. Wecan knowthe hematological data of 16 patients except for the blastic phase according to these reports after all. All except one patient had absolute monocytosis higher than l.OxlO9//; ll (69%) had relative monocytosis greater than 8%. There were additional cases with p l90BCR-ABLwho had shown monocytosis during the course of their illness who had first presented at first as blastic phase of CML(6), myeloproliferative (7) or myelodysplastic syndrome (7, 8) . Therefore, it may be of clinical and biological significance that CMLpatients with pl90BCR-ABL have monocytosis.
The diversity of BCR-ABLfusion proteins and their relationship to clinical features are still unclear. In a murine bone marrow transduction/transplantation model (9), the three forms of BCR-ABLwere equally potent in the induction of a CMLlike myeloproliferative syndrome, and pl90BCR-ABLcould also induce lymphoid leukemia with a shorter latency than p2 1 0. It is suggested that the rarity ofpl90BCR-ABLin human CML may reflect the infrequent BCRintron 1 breakpoints during the genesis of the Ph chromosomein stem cells, rather than intrinsic differences in myeloid leukemogenicity between p i 90 and p210. In another murine model, Honda et al generated transgenic mice expressing p210BCR-ABL driven by the promoter of the mousetec gene, which enabled expression of a cytoplasmic tyrosine kinase preferentially in early hematopoietic progenitors (10) . The transgenic progeny reproducibly exhibited marked granulocyte hyperplasia with thrombocytosis after a long latent period, which closely resembles the clinical course of humanCML. This model may be useful to elucidate the real biological nature of pl90BCR-ABL. 
